Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2004

View Archived Issues

Shionogi researchers claim iNOS inhibitors and their therapeutic use

New leucomycin A7 derivatives and their use in Gram-positive bacterial infections

Abbott presents new PDE4 and TNF-alpha production inhibitors

Novel MCH antagonists in early development at Aventis

Novel glycogen phosphorylase inhibitors developed by Aventis team

New vanilloid VR1 antagonists and their use in pain, urinary incontinence, etc.

New beta-lactamase-resistant carbapenems discovered at Sankyo

Pyrazole-based antiplatelet agents newly developed at Daiichi

Selective inhibitors of PKB/Akt designed at Astex

ABP-309: a second-generation VEGFR tyrosine kinase inhibitor with a promising preclinical profile

First clinical results reported for AMG-706 in patients with advanced tumors

Inhibition of SOD1 via copper depletion results in inhibition of angiogenesis

Novel VEGFR2/PDGFR kinase inhibitor with antitumor and antiangiogenic activity presented by Bayer

Pharmacyclics identifies potential development candidate from a series of sapphyrin derivatives

Recordati to market prulifloxacin in Spain

Millennium submits supplemental NDA for Velcade

Bayer inlicenses Seattle Genetics' ADC technology

New approvals for Enbrel

L-BLP-25 liposome vaccine receives fast track status for NSCLC

Phase I cleared to begin for CDA-1 for C. difficile associated diarrhea

Genaera receives SBIR grant for development of trodusquemine

New phase II study for M-40403 in cancer pain

Enrollment completed in phase IIb African sleeping sickness trial of DB-289

New dosing option of Omnicef approved for pediatric use

Expanded phase II trial for squalamine opens enrollment

Epimmune plans phase II study of EP-2101 cancer vaccine

Exelixis to acquire X-Ceptor Therapeutics

Merck voluntarily withdraws Vioxx

New data on the efficacy of onercept in active Crohn's disease

Update on the efficacy of ABT-874 in active Crohn's disease

Prous Science launches new enhanced version of LifeSciChannel.com

Uriach selects UR-14048 for further development for parenteral treatment of acute pain

NP-031112 and NP-00111 demonstrate neuroprotectant effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...